John Burnett Jr., MD
John Burnett Jr., MD is the Marriott Family Professor of Cardiovascular Research, Director of the Cardiorenal Research Laboratory, and Mayo Distinguished Investigator.
His research has advanced our understanding of humoral mechanisms in heart failure and hypertension with a special focus on the natriuretic peptide/guanylyl cyclase/cGMP pathway. This research has led to the development of innovative therapeutics and novel diagnostics, which are currently in clinical practice and cilinical trails.
Dr. Burnett’s research advances the preclinical development of a novel designer peptide, which was engineered by Dr. Brunett for the treatment of heart failure (HF) to delay disease progression. This innovative peptide co-activates Mas and GC-A receptors representing a first in class multivalent therapeutic. He hypothesizes that this peptide, both in vitro and in vivo, will possess greater cardiorenal protective properties than Mas or GC-A activation alone. Dr. Burnett’s studies also address the unmet clinical need for new drugs for HF.
Dr. Burnett received his BS from the University of Illinois at Urbana-Champaign and his MD from Loyola University & Stritch School of Medicine. He did his residency and internship in internal medicine at the Mayo Graduate School of Medicine. Dr. Burnett is a member of the Association of American Physicians and The American Society for Clinical Investigation. He holds 13 patents and has contributed to the founding of 3 biotechnology companies.